VEGZELMA

Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion/ Notification[1] issued on	Commission Decision Issued[2] / amended on	Product Information affected[3]	Summary
N/0013	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	17/10/2024		PL	
N/0011	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	24/07/2024		PL	

[1] Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.
[2] A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.
[3] SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

II/0010/G	This was an application for a group of variations. B.II.f.1.e - Stability of FP - Change to an approved stability protocol B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes	11/07/2024	n/a		
IB/0008	B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol	13/05/2024		SmPC	
IAIN/0009	B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site	03/05/2024	n/a		
IAIN/0007	B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing	15/12/2023	06/05/2024	Annex II and PL	

IAIN/0006	B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing	15/12/2023	06/05/2024	Annex II and PL	
N/0005	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	06/09/2023	06/05/2024	PL	
IAIN/0004	B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site	16/08/2023	n/a		
IB/0003	B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol	18/04/2023	06/05/2024	SmPC	Product information section 6.3 is updated to reflect the shelf-life extension of the finished product VEGZELMA 25 mg/mL concentrate for solution for infusion (EU/1/22/1667/001, EU/1/22/1667/003) as packaged for sale from 2 years to 3 years when stored at 5 ºC ± 3 ºC.
IB/0002	C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH	22/03/2023	06/05/2024	SmPC and PL	
N/0001	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	22/09/2022	06/05/2024	PL	